AbbVie’s Susie Jun Joins Allogene as Chief Development Officer

Allogene Therapeutics has appointed Susie Jun to serve as chief development officer. Jun comes to the cancer immunotherapy developer from AbbVie (NYSE: [[ticker:ABBV]]), where she was vice president and head of development for the company’s Stemcentrx subsidiary. Her experience also includes posts at Gilead Sciences (NASDAQ: [[ticker:GILD]]) and Amgen (NASDAQ: [[ticker:AMGN]]). South San Francisco, CA-based Allogene raised $300 million in Series A financing in April to take over U.S. development of a Pfizer (NYSE: [[ticker:PFE]]) program pursuing an “off-the-shelf” cell therapy for cancer.

Author: Frank Vinluan

Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times. View all posts by Frank Vinluan